Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 6, 2005
- Accepted for publication September 23, 2005
- Published online March 1, 2006.
Copyright & Usage
© 2006 by Society of Nuclear Medicine
Author Information
- Renzo Cescato, PhD 1 ,
- Stefan Schulz, PhD 2 ,
- Beatrice Waser 1 ,
- Véronique Eltschinger 1 ,
- Jean E. Rivier, PhD 3 ,
- Hans-Jürgen Wester, PhD 4 ,
- Michael Culler, PhD 5 ,
- Mihaela Ginj, PhD 6 ,
- Qisheng Liu, MD, PhD 7 ,
- Agnes Schonbrunn, PhD 7 and
- Jean Claude Reubi, MD 1
- 1Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland; 2Institute of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany; 3Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California; 4Nuklearmedizinische Klinik und Poliklinik, Technical University of Munich, Munich, Germany; 5Endocrine Research, Beaufour-Ipsen Group, Milford, Massachusetts; 6Division of Radiological Chemistry, University Hospital, Basel, Switzerland; and 7Department of Integrative Biology and Pharmacology, University of Texas Health Science Center–Houston, Houston, Texas
- For correspondence or reprints contact: Jean Claude Reubi, MD, Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland. E-mail: reubi{at}patho.unibe.ch
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
- Upregulation of Key Molecules for Targeted Imaging and Therapy
- The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts
- Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
- Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands
- Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- PET of Somatostatin Receptor-Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
- 18F-Labeled Bombesin Analog for Specific and Effective Targeting of Prostate Tumors Expressing Gastrin-Releasing Peptide Receptors
- Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors
- Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery
- Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues
- Peptide-Based Probes for Cancer Imaging
- New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting
- Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
- Novel insights in somatostatin receptor physiology
- Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
- Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications